Delivering a step-change in the selectivity and potency of targeted biotherapeutics

Bi-Cygni

®

Based on differentiated biology, Bi-Cygni® converts BiVictriX’s novel panel of cancer-restricted target antigen combinations into potent bispecific therapeutics with improved therapeutic index

BiVictriX's Novel Panel of Cancer-Restricted
 Antigen Combinations 
Bi-Cygni
Generation of leads with improved potency and selectivity

®

Lead Optimization
in to Multiple Therapeutic Modalities
BiVictriX links Bi-Cygni   to expertise in the design, discovery and development of Antibody Drug Conjugates (ADCs).

®

  • Conventional Antibody Drug Conjugates (ADCs) target single antigens expressed on the tumour cell surface

  • Many of the targeted antigens are not cancer-restricted and are often widely expressed on healthy cells, resulting in debilitating on-target, off-tissue toxicities

  • BiVictriX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce truly cancer selective therapeutics

  • The Bi-Cygni   technology was developed to exploit this concept and expedite the development of bispecific therapeutics with improved therapeutic index

  • BiVictriX's Bi-Cygni   ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs

®

®

BiVictriX Therapeutics Ltd.

 

Bio Hub   |   Alderley Park  |   Alderley Edge   |    Cheshire    |    SK10 4TG   |    UK

 

The OpTIC Centre  |  St Asaph Business Park  |  St Asaph  |   Wales  |   LL17 0JD  |   UK

 

info@bivictrix.com